Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial-Reference-Cited by-同舟云学术

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

Published:2024-09 Issue:9 Volume:25 Page:1176-1187
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Vera Pierre,Thureau Sébastien,Le Tinier Florence,Chaumet-Riffaud Philippe,Hapdey Sébastien,Kolesnikov-Gauthier Hélène,Martin Etienne,Berriolo-Riedinger Alina,Pourel Nicolas,Broglia Jean Marc,Boissellier Pierre,Guillemard Sophie,Salem Naji,Brenot-Rossi Isabelle,Le Péchoux Cécile,Berthold Céline,Giroux-Leprieur Etienne,Moreau Damien,Guillerm Sophie,Benali Khadija,Tessonnier Laurent,Audigier-Valette Clarisse,Lerouge Delphine,Quak Elske,Massabeau Carole,Courbon Frédéric,Moisson Patricia,Larrouy Anne,Modzelewski Romain,Gouel Pierrick,Ghazzar Nadia,Langlais Alexandra,Amour Elodie,Zalcman Gérard,Giraud Philippe

Funder

French National Cancer Institute

Publisher

Elsevier BV

Reference23 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

2. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

3. Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer;Vaz;Radiother Oncol,2022

4. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC);Edet-Sanson;Radiother Oncol,2012

5. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2);Vera;Eur J Nucl Med Mol Imaging,2014